Humana (NYSE:HUM) Receives New Coverage from Analysts at KeyCorp

KeyCorp started coverage on shares of Humana (NYSE:HUM) in a research report report published on Friday, Marketbeat reports. The firm issued a sector weight rating on the insurance provider’s stock.

Several other research firms also recently weighed in on HUM. UBS Group decreased their price target on shares of Humana from $380.00 to $250.00 and set a neutral rating for the company in a research note on Friday, October 4th. Truist Financial lifted their price target on shares of Humana from $355.00 to $400.00 and gave the company a hold rating in a research note on Monday, July 15th. Barclays decreased their price target on shares of Humana from $364.00 to $250.00 and set an equal weight rating for the company in a research note on Thursday, October 10th. Bank of America downgraded shares of Humana from a neutral rating to an underperform rating and decreased their price target for the company from $376.00 to $247.00 in a research note on Wednesday, October 2nd. Finally, Sanford C. Bernstein raised shares of Humana from a market perform rating to an outperform rating and set a $308.00 price target for the company in a research note on Tuesday, October 8th. One research analyst has rated the stock with a sell rating, nineteen have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of Hold and a consensus target price of $315.33.

Humana Price Performance

HUM stock opened at $267.60 on Friday. The firm has a market cap of $32.25 billion, a price-to-earnings ratio of 16.66, a PEG ratio of 1.91 and a beta of 0.50. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana has a 12-month low of $213.31 and a 12-month high of $530.54. The company’s fifty day simple moving average is $322.99 and its 200 day simple moving average is $339.86.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. Humana’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.94 earnings per share. On average, analysts expect that Humana will post 16.06 earnings per share for the current year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.32%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CarsonAllaria Wealth Management Ltd. lifted its stake in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares in the last quarter. Atwood & Palmer Inc. purchased a new stake in shares of Humana during the 3rd quarter valued at approximately $29,000. Hantz Financial Services Inc. purchased a new stake in shares of Humana during the 2nd quarter valued at approximately $35,000. Family Firm Inc. purchased a new stake in shares of Humana during the 2nd quarter valued at approximately $37,000. Finally, Hollencrest Capital Management purchased a new stake in shares of Humana during the 2nd quarter valued at approximately $40,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.